Evidence map›Paper›PMID 38716676›Full record

ReviewAndrology2024

Emerging approaches to male contraception.

Wei Yan, John K Amory

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Andrology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Wei YanThe Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, USA.
John K AmoryDepartment of Medicine, Center for Research in Reproduction and Contraception, University of Washington, Seattle, Washington, USA.

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
Mechanism Underlying the Transduction of Epimutations from the Soma to the Male GermlineP50HD098593 · NICHD · UNIVERSITY OF NEVADA RENO · PI ZHENG, HUI · 2019 to 2024
$7.2M
ALDH1A1/A2 Inhibitors for Male ContraceptionR01HD098039 · NICHD · UNIVERSITY OF WASHINGTON · PI AMORY, JOHN K. · 2019 to 2023
$1.9M
Epitranscriptomic regulation of spermatogenesis and male fertilityR01HD099924 · NICHD · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI YAN, WEI · 2020 to 2024
$1.9M
IND-enabling studies to develop triptonide into the first nonhormonal male pillR61HD114186 · NICHD · WASHINGTON STATE UNIVERSITY · PI NICKELS, LOGAN, YAN, WEI · 2024 to 2025
$781k
Eunice Kennedy ShriverFerring PharmaceuticalsNCATS NIH HHS UL1 TR001881NICHD NIH HHS P50 HD098593NICHD NIH HHS R01 HD098039NICHD NIH HHS R01 HD099924NICHD NIH HHS R61 HD114186
6 · The paper itself

Abstract

backgroundCurrently, approximately half of all pregnancies worldwide are unintended. Contraceptive use significantly reduces the risk of unintended pregnancy; however, options for men are particularly limited. Consequently, efforts are underway to develop novel, safe, and effective male contraceptives.

resultsThis review discusses research into emerging male contraceptive methods that either inhibit sperm production or impair sperm function. It focuses on those in the preclinical or early clinical stages of development.

Indexed as

ContraceptionContraceptive Agents, MaleAnimalsHumansMaleSpermatogenesisSpermatozoaContraceptive Agents, Malecondomsmale contraceptionspermatozoaunintended pregnancyvasectomy

Identifiers

PMID38716676
PMCPMC11461125

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.